ArrayExpress is moving to BioStudies. This view of ArrayExpress will be deprecated soon.
Please visit the new experiment page at https://www.ebi.ac.uk/biostudies/arrayexpress/studies/E-MTAB-6486.
E-MTAB-6486 - RNA-seq to investigate impact of treatment of KRAS mutant NCI-H2009 lung adenocarcinoma cells with the multi-ERBB inhibitor Neratinib
Released on 1 June 2018, last updated on 16 March 2020
KRAS mutation is widely presumed to confer independence from upstream RTK signalling, however emerging evidence from mouse models of lung cancer suggests that ERBB RTKs may amplify signalling through RAS isoforms and participate in mutant RAS-driven lung cancer. This is one of 3 datasets where we examined the transcriptional impact of treatment of KRAS mutant human lung cancer cell lines with the multi-ERBB inhibitor Neratinib
RNA-seq of coding RNA, compound treatment design
The ERBB network facilitates KRAS-driven lung tumorigenesis. Kruspig B, Monteverde T, Neidler S, Hock A, Kerr E, Nixon C, Clark W, Hedley A, Laing S, Coffelt SB, Le Quesne J, Dick C, Vousden KH, Martins CP, Murphy DJ. Science Translational Medicine 10(468) (2018)